Patents by Inventor BRADFORD C. SIPPY
BRADFORD C. SIPPY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11872206Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: GrantFiled: July 1, 2022Date of Patent: January 16, 2024Assignee: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Publication number: 20240000799Abstract: Provided herein are compositions (e.g., pharmaceutical compositions) comprising deuterated testosterone, deuterated methyltestosterone, deuterated androstenedione, or derivatives thereof. The provided compositions and related methods may be useful for treating and/or preventing various diseases and conditions, such as hypogonadism, delay of growth and puberty, weight loss associated with HIV-associated wasting, vulvar dystrophies, micropenis, breast cancer, and sexual disorders.Type: ApplicationFiled: December 2, 2021Publication date: January 4, 2024Applicant: Lennham Pharmaceuticals, Inc.Inventors: Bradford C. Sippy, Benjamin D. Enerson
-
Patent number: 11858909Abstract: Disclosed herein are compounds, such as compounds of Formulae (I), (II), and (III), and d3-etoricoxib, and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, metabolites, and prodrugs thereof, and compositions, methods, uses, and kits thereof. The compounds disclosed herein are COX inhibitors and are therefore useful for the treatment and/or prevention of various conditions (e.g., inflammation, pain, or fever).Type: GrantFiled: August 27, 2021Date of Patent: January 2, 2024Assignee: Tremeau Pharmaceuticals, Inc.Inventor: Bradford C. Sippy
-
Publication number: 20230371555Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.Type: ApplicationFiled: April 21, 2023Publication date: November 23, 2023Applicant: Lennham Pharmaceuticals, Inc.Inventor: Bradford C. Sippy
-
Publication number: 20230355632Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated paraxanthine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.Type: ApplicationFiled: September 10, 2021Publication date: November 9, 2023Applicant: Lennham Pharmaceuticals, Inc.Inventor: Bradford C. Sippy
-
Patent number: 11666073Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.Type: GrantFiled: June 12, 2020Date of Patent: June 6, 2023Assignee: Lennham Pharmaceuticals, Inc.Inventor: Bradford C. Sippy
-
Patent number: 11633371Abstract: The present disclosure provides compositions comprising deuterated forms of acetaminophen. When administered to human subjects, such compositions form less of the toxic metabolite NAPQI, and therefore are useful in methods of treating various diseases and conditions with a reduced risk of liver injury or other side effects associated with non-deuterated forms of acetaminophen.Type: GrantFiled: February 8, 2022Date of Patent: April 25, 2023Assignee: Lennham Pharmaceuticals, Inc.Inventor: Bradford C. Sippy
-
Publication number: 20230124138Abstract: Provided herein are compositions (e.g., pharmaceutical compositions) comprising deuterated testosterone, deuterated methyltestosterone, or derivatives thereof. The provided compositions and related methods may be useful for treating and/or preventing various diseases and conditions, such as hypogonadism, delay of growth and puberty, weight loss associated with HIV-associated wasting, vulvar dystrophies, micropenis, breast cancer, and sexual disorders.Type: ApplicationFiled: October 14, 2022Publication date: April 20, 2023Applicant: Lennham Pharmaceuticals, Inc.Inventors: Bradford C. Sippy, Benjamin D. Enerson
-
Patent number: 11617735Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: GrantFiled: June 28, 2022Date of Patent: April 4, 2023Assignee: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Publication number: 20230062523Abstract: Provided herein are methods for the safe use of compositions comprising psilocin and prodrugs of psilocin for treating and/or preventing various diseases and conditions, such as mood or psychiatric disorders.Type: ApplicationFiled: May 11, 2022Publication date: March 2, 2023Inventor: Bradford C. Sippy
-
Patent number: 11576890Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: GrantFiled: February 26, 2021Date of Patent: February 14, 2023Assignee: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Patent number: 11559509Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: GrantFiled: June 28, 2022Date of Patent: January 24, 2023Assignee: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Patent number: 11547127Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.Type: GrantFiled: March 31, 2022Date of Patent: January 10, 2023Assignee: Lennham Pharmaceuticals, Inc.Inventor: Bradford C. Sippy
-
Publication number: 20220409568Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: ApplicationFiled: June 28, 2022Publication date: December 29, 2022Applicant: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Publication number: 20220409575Abstract: The subject matter disclosed herein relates to novel doses and dosage forms of rofecoxib having a therapeutic benefit.Type: ApplicationFiled: June 30, 2022Publication date: December 29, 2022Applicant: Tremeau Pharmaceuticals, Inc.Inventors: Bradford C. Sippy, Raymond D. Skwierczynski, Travis E. Helm
-
Publication number: 20220378736Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: ApplicationFiled: July 1, 2022Publication date: December 1, 2022Applicant: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Publication number: 20220362206Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: ApplicationFiled: June 28, 2022Publication date: November 17, 2022Applicant: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Publication number: 20220332696Abstract: Disclosed herein are compounds, such as compounds of Formulae (I), (II), and (III), and d3-etoricoxib, and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, metabolites, and prodrugs thereof, and compositions, methods, uses, and kits thereof. The compounds disclosed herein are COX inhibitors and are therefore useful for the treatment and/or prevention of various conditions (e.g., inflammation, pain, or fever).Type: ApplicationFiled: August 27, 2021Publication date: October 20, 2022Applicant: Tremeau Pharmaceuticals, Inc.Inventor: Bradford C. Sippy
-
Patent number: 11471469Abstract: Provided herein are compositions (e.g., pharmaceutical compositions) comprising deuterated testosterone, deuterated methyltestosterone, or derivatives thereof. The provided compositions and related methods may be useful for treating and/or preventing various diseases and conditions, such as hypogonadism, delay of growth and puberty, weight loss associated with HIV-associated wasting, vulvar dystrophies, micropenis, breast cancer, and sexual disorders.Type: GrantFiled: December 20, 2021Date of Patent: October 18, 2022Assignee: Lennham Pharmaceuticals, Inc.Inventors: Bradford C. Sippy, Benjamin D. Enerson
-
Publication number: 20220313630Abstract: The present disclosure provides compositions comprising deuterated forms of acetaminophen. When administered to human subjects, such compositions form less of the toxic metabolite NAPQI, and therefore are useful in methods of treating various diseases and conditions with a reduced risk of liver injury or other side effects associated with non-deuterated forms of acetaminophen.Type: ApplicationFiled: June 3, 2020Publication date: October 6, 2022Applicant: Lennham Pharmaceuticals, Inc.Inventor: Bradford C. Sippy